The high prices Americans pay for drugs has emerged as a major health policy concern. A majority of voters in both the Democratic and Republican parties want the government to take action to lower prices, and lawmakers in both houses of Congress have introduced bills aimed at doing so. Drug companies, meanwhile, argue (as they long have) that negotiating or regulating prices would cripple research budgets, stifle innovation, and lead to fewer treatments in the future.